Implement a comprehensive HIV prevention approach         There are >1.2 million people at substantial risk of HIV infection in the United States1   Nearly 50,000 new cases of HIV occur in the United States each year2   An ongoing national effort to help reduce HIV infection rates is under way3           WHAT DO HEALTH AUTHORITIES RECOMMEND?           The latest federal and global health guidelines (including those from the CDC, ACOG, IAS–USA, and WHO), clinical studies, as well as the National HIV/AIDS Strategy, recognize the importance of a comprehensive prevention approach.3-8           A COMPREHENSIVE APPROACH           The first step in HIV prevention is identifying who is at risk. Start by talking to patients about their sexual health. Ongoing sexual health conversations are an essential component of identifying which of your patients may be at risk of acquiring HIV.9         FOR ALL PATIENTS         Combine routine HIV and STI testing with sexual history conversations and education on the importance of condoms.         HIV-INFECTED PATIENTS     Educate about initiating and adhering to treatment, and the importance of condoms to help prevent HIV transmission to uninfected partners.       HIV-UNINFECTED PATIENTS AT RISK OF INFECTION     Educate about the importance of condoms, and consider additional prevention methods such as behavioral counseling, PrEP (pre-exposure prophylaxis), and PEP (post-exposure prophylaxis) for appropriate patients.9,10                 To learn more about HIV prevention, and to register for updates, visit         Thank you for your ongoing commitment to HIV prevention,       The Gilead HIV Prevention Team       ACOG=American College of Obstetricians and Gynecologists CDC=Centers for Disease Control and Prevention IAS–USA=International Antiviral Society–USA WHO=World Health Organization       References: 1. Smith DK, Van Handel M, Wolitski RJ, et al. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(46):1291-1295. 2. Centers for Disease Control and Prevention. Today's HIV/AIDS epidemic. ‌h‌ttp:/‌/‌www.c‌dc.‌gov‌/‌nchhstp/ne‌wsroom/docs/factsheets/t‌odaysepidemic-508.pdf. Published February 2016. Accessed July 28, 2016. 3. White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States: updated to 2020. ‌h‌ttps:/‌/www.a‌ids.‌gov‌/federal-‌resources/national-hiv-aids-strategy/nhas-update.pdf. Published July 2015. Accessed May 9, 2016. 4. Centers for Disease Control and Prevention. HIV prevention in the United States: new opportunities, new expectations. ‌h‌ttp:/‌/ww‌w.cdc.‌gov‌/hiv/pdf/policies/cdc-hiv-prevention-‌bluebook.pdf. Published December 2015. Accessed May 16, 2016. 5. The American College of Obstetricians and Gynecologists. Committee on Gynecologic Practice. Preexposure prophylaxis for the prevention of human immunodeficiency virus. Committee Opinion No. 595. Obstet Gynecol. 2014;123:1133-1136. 6. Marrazzo JM, del Rio C, Holtgrave DR, et al. HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society–USA panel. JAMA. 2014;312(4):390-409. 7. Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society–USA panel. JAMA. 2016;316(2):191-210. 8. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach—second edition. ‌h‌ttp:/‌/www.w‌ho.int‌/‌hiv/pub/arv/arv-‌2016/en/. Published June 2016. Accessed June 27, 2016. 9. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States—2014: a clinical practice guideline. h‌ttp:/‌/www.c‌dc.‌gov‌/hiv/‌pdf/prepguidelines2014.pdf. Published 2014. Accessed May 9, 2016. 10. Centers for Disease Control and Prevention. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016. https://stacks.cdc.gov/view/cdc/38856. Published 2016. Accessed May 18, 2016.         Gilead Website  |   Terms of Use  |   Privacy Policy  |   Contact Us  |   Unsubscribe             GILEAD, the GILEAD Logo, and the P‌reventHIV.com Logo are trademarks of Gilead Sciences, Inc., or one of its related companies. © 2016 Gilead Sciences, Inc. 3‌33 L‌akeside D‌rive, F‌oster City, C‌A 9‌4404 All rights reserved. UNBP2651 1‌0/16